Article summary
The Competition and Markets Authority (CMA) has confirmed its finding that Pfizer and Flynn abused their dominant positions and overcharged the NHS for four years for phenytoin sodium capsules, a life-saving epilepsy drug. As such, the CMA issued fines amounting to £63m and £6.7m to the pharma companies respectively. The CMA found that Pfizer and Flynn re-branded the drug, so that it was no longer subject to price regulations, forcing the NHS to buy the medicine at the inflated price. The costs for the NHS rose from £2m to £50m in a single year between 2012 and 2013 as a result.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial